KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Cash from Operations (2017 - 2025)

Aquestive Therapeutics has reported Cash from Operations over the past 9 years, most recently at 8469000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 8469000.0 for Q4 2025, down 30.51% from a year ago — trailing twelve months through Dec 2025 was 52432000.0 (down 46.63% YoY), and the annual figure for FY2025 was 52432000.0, down 46.63%.
  • Cash from Operations for Q4 2025 was 8469000.0 at Aquestive Therapeutics, up from 12649000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for AQST hit a ceiling of 8816000.0 in Q1 2023 and a floor of 23400000.0 in Q1 2025.
  • Median Cash from Operations over the past 5 years was 7910500.0 (2023), compared with a mean of 6868450.0.
  • Biggest five-year swings in Cash from Operations: soared 204.4% in 2022 and later plummeted 406.18% in 2024.
  • Aquestive Therapeutics' Cash from Operations stood at 8061000.0 in 2021, then soared by 204.4% to 8416000.0 in 2022, then crashed by 158.72% to 4942000.0 in 2023, then tumbled by 31.3% to 6489000.0 in 2024, then plummeted by 30.51% to 8469000.0 in 2025.
  • The last three reported values for Cash from Operations were 8469000.0 (Q4 2025), 12649000.0 (Q3 2025), and 7914000.0 (Q2 2025) per Business Quant data.